ConductScience.org, home

Paper39436624

A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin.

Araki T and 9 others. Clin J Gastroenterol, 2025. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin. Papers, record 39436624. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39436624

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A case of successful conversion surgery for unresectable gallbladder cancer treated with durvalumab in combination with gemcitabine plus cisplatin.
PubMed
Journal
Clin J Gastroenterol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Case Reports
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
1.78, provisional
iCite
Revised in PubMed
2026-10-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Araki TTatsuhiro
2Muranushi RRyo
3Takagi KKohji
4Tanaka HHaruyoshi
5Shibuya KKazuto
6Ando TTakayuki
7Yoshioka IIsaku
8Hirabayashi KKenichi
9Yasuda IIchiro
10Fujii TTsutomuhttps://orcid.org/0000-0003-0625-1911

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Gallbladder NeoplasmsMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Antibodies, MonoclonalMajor topic
Humans
Female
Gemcitabine
Deoxycytidine
Cisplatin
Aged
Lymph Node Excision

Source PubMed

Download CSV of topics

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135039070Locally advanced gallbladder cancer treated with effective chemotherapy and subsequent curative resection: a case report.J Med Case Rep2022https://conductscience.org/library/papers/35039070PubMed
233860135Essential updates 2019/2020: Surgical treatment of gallbladder cancer.Ann Gastroenterol Surg2021https://conductscience.org/library/papers/33860135PubMed
327025903Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).Jpn J Clin Oncol2016https://conductscience.org/library/papers/27025903PubMed
437076889Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring.Diagn Pathol2023https://conductscience.org/library/papers/37076889PubMed
538319896Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.NEJM Evid2022https://conductscience.org/library/papers/38319896PubMed
636242892Curative surgical resection for initially unresectable metastatic gallbladder cancer following neoadjuvant chemotherapy: Case report and review of literature.Int J Surg Case Rep2022https://conductscience.org/library/papers/36242892PubMed
734402435Conversion surgery for initially unresectable extrahepatic biliary tract cancer.Ann Hepatobiliary Pancreat Surg2021https://conductscience.org/library/papers/34402435PubMed
837184729Induction chemotherapy and hepatic artery embolization followed by extended resection for locally advanced gallbladder cancer: a case report.Surg Case Rep2023https://conductscience.org/library/papers/37184729PubMed
935332404Conversion surgery following gemcitabine plus cisplatin therapy for initially unresectable gallbladder cancer with peritoneal carcinomatosis: a case report.Surg Case Rep2022https://conductscience.org/library/papers/35332404PubMed
1021490453Gallbladder cancer involving the extrahepatic bile duct is worthy of resection.Ann Surg2011https://conductscience.org/library/papers/21490453PubMed
1136575822Survival after extended resections for gallbladder cancer.Ann Hepatobiliary Pancreat Surg2023https://conductscience.org/library/papers/36575822PubMed
1236052238Successful conversion surgery for locally advanced gallbladder cancer after gemcitabine and nab-paclitaxel chemotherapy.Front Oncol2022https://conductscience.org/library/papers/36052238PubMed
1331825009Long term recurrence free survival in a stage IV gallbladder cancer treated with chemotherapy plus trastuzumab and salvage liver resection.Ann Hepatobiliary Pancreat Surg2019https://conductscience.org/library/papers/31825009PubMed
1438123314PD-L1 inhibitor plus gemcitabine and cisplatin therapy followed by conversion surgery for initially unresectable advanced gallbladder cancer.BMJ Case Rep2023https://conductscience.org/library/papers/38123314PubMed
1535666061Impact of delay in adjuvant therapy for gallbladder adenocarcinoma.J Hepatobiliary Pancreat Sci2023https://conductscience.org/library/papers/35666061PubMed
1635079922Pathological complete response achieved by gemcitabine plus cisplatin therapy for initially unresectable advanced gallbladder cancer: a case report.Surg Case Rep2022https://conductscience.org/library/papers/35079922PubMed
1728497252Gallbladder Cancer Presenting with Jaundice: Uniformly Fatal or Still Potentially Curable?J Gastrointest Surg2017https://conductscience.org/library/papers/28497252PubMed
1827864927Indications for major hepatectomy and combined procedures for advanced gallbladder cancer.Br J Surg2017https://conductscience.org/library/papers/27864927PubMed
1937369470Expression and Prognostic Significance of PD-L1 and NY-ESO1 in Gallbladder Carcinoma.In Vivo2023https://conductscience.org/library/papers/37369470PubMed
2035900311Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA).J Hepatobiliary Pancreat Sci2023https://conductscience.org/library/papers/35900311PubMed

See all 22 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
42519320Case Report: Successful R0 resection following conversion immunochemotherapy in a patient with biliary tract cancer and multiple metastases discovered after laparoscopic gallstone surgery.Front Immunol2026https://conductscience.org/library/papers/42519320PubMed
42339344A Case of Unresectable Ampulla of Vater Carcinoma Successfully Treated with Conversion Surgery Following Sequential Systemic Chemotherapy Including Durvalumab.Surg Case Rep2026https://conductscience.org/library/papers/42339344PubMed
41929550A case of perihilar cholangiocarcinoma with peritoneal dissemination that achieved a pathological complete response using immune checkpoint inhibitors: A case report.Int Cancer Conf J2026https://conductscience.org/library/papers/41929550PubMed
41236594Durable response to chemotherapy enabling conversion surgery in stage IVB gallbladder cancer: a case successfully treated with durvalumab combined with gemcitabine plus cisplatin.Clin J Gastroenterol2026https://conductscience.org/library/papers/41236594PubMed
41080570Long-term survival after targeted therapy plus immunotherapy without chemotherapy in advanced gallbladder carcinoma: a case report and literature review.Front Immunol2025https://conductscience.org/library/papers/41080570PubMed
40242270Immunotherapy for primary squamous cell carcinoma of the liver: A case report.Oncol Lett2025https://conductscience.org/library/papers/40242270PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39436624

GET https://conductscience.org/api/papers/v1/39436624/references?page=2